Zhao Changlin, et al.
Clifford Hospital, Oncological Integrative Treatment Center
Publication: Chinese Journal of Cancer Prevention and Treatment
Objective: To study the effect of Sirikaya lactone Bullatacin on inducing the apoptosis of human liver cancer cell strain HpG2.
Method: The effect of Bullatacin on the cell proliferation of HpG2 was tested by MTT. The effects of Bullatacin on apoptosis and generation cycle of HpG2 and express of Fas protein were analyzed by propidium iodide staining (PI) and fluorescently-labeled monoclonal antibody (mAb) combining flow cytometry (FCM). The effect of Bullatacin on the express of Fas gene was tested by RT-PCR.
Result: Bullatacin (100μg/mL) can significantly depress the generation of human liver cancer cell strain HpG2, with the depression rate of 66.3% in 96 hours. HpG2 was depressed at Stage G0/G1, and prevented to get into Stage G2/M with apoptosis inducement at the same time. Bullatacin can significantly raise the express of Fas protein on the cell surface of HpG2 (P=0.006), with better effect than C-DDP (P=0.03). Further research showed that Bullatacin can induce the express of Fas gene.
Conclusion: Bullatacin can induce apoptosis of HpG2 cell. The probable mechanism is inducing the express of Fas gene which leads to the rise of Fas protein. This research provides theoretical and laboratory evidences of the study of Bullatacin as an anticancer drug.
Keywords: Sirikaya Lactone; Bullatacin; Liver Cancer; Cell Strain; Apoptosis
